We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+39.75%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$165M
AUM Growth
+$52.7M
Cap. Flow
+$21.1M
Cap. Flow %
12.75%
Top 10 Hldgs %
78.72%
Holding
53
New
7
Increased
8
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$14.7M
2
BLUE
bluebird bio
BLUE
+$3.49M
3
SLNO
Soleno Therapeutics
SLNO
+$1.81M
4
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$1.05M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$834K

Top Sells

Rank Stock Value
1
VRML
Vermillion, Inc.
VRML
+$2.68M
2
GILD icon
Gilead Sciences
GILD
+$766K
3
EQM
EQM Midstream Partners, LP
EQM
+$605K
4
IFRX icon
InflaRx
IFRX
+$259K
5
WKHS icon
Workhorse Group
WKHS
+$32.5K

Sector Composition

Rank Sector Weight
1 Healthcare 95.54%
2 Energy 1.09%
3 Consumer Discretionary 0.16%
4 Consumer Staples 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$46.6M 28.16%
792,386
+6,601
+0.8% +$395K
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$33.3M 20.1%
219,380
– –
AWH
3
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$12.7M 7.65%
+219,816
New +$14.7M
QDEL icon
4
QuidelOrtho
QDEL
$1.19B
$11.4M 6.89%
50,944
+2,100
+4% +$329K
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.2B
$9.52M 5.75%
78,000
+4,000
+5% +$442K
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$4.38B
$4.51M 2.72%
93,000
+1,000
+1% +$48K
BLUE
7
DELISTED
bluebird bio
BLUE
$3.66M 2.21%
+4,632
New +$3.49M
KPTI icon
8
Karyopharm Therapeutics
KPTI
$216M
$3.18M 1.92%
11,200
+1,333
+14% +$394K
BIIB icon
9
Biogen
BIIB
$30.4B
$2.94M 1.78%
11,000
– –
BMY.RT
10
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$2.53M 1.53%
706,848
– –
OXFD
11
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.21M 1.34%
170,303
– –
UTHR icon
12
United Therapeutics
UTHR
$22.7B
$2.18M 1.32%
18,000
– –
SLNO
13
DELISTED
Soleno Therapeutics
SLNO
$1.84M 1.11%
55,127
+41,694
+310% +$1.81M
MASI
14
DELISTED
Masimo
MASI
$1.82M 1.1%
8,000
– –
AMRN
15
Amarin Corp
AMRN
$292M
$1.8M 1.09%
13,000
+4,000
+44% +$550K
XLRN
16
DELISTED
Acceleron Pharma
XLRN
$1.78M 1.08%
18,672
– –
CCXI
17
DELISTED
ChemoCentryx, Inc.
CCXI
$1.73M 1.04%
30,000
– –
CFRX
18
DELISTED
ContraFect Corporation
CFRX
$1.63M 0.99%
3,196
– –
ARNA
19
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.39M 0.84%
22,000
– –
ALBO
20
DELISTED
Albireo Pharma Inc
ALBO
$1.27M 0.77%
48,000
– –
EPZM
21
DELISTED
Epizyme, Inc
EPZM
$1.12M 0.68%
70,000
+10,000
+17% +$175K
ETRN
22
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.11M 0.67%
+133,050
New +$1.05M
GTHX
23
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$970K 0.59%
40,000
– –
MYOK
24
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$966K 0.58%
+10,000
New +$834K
HROW icon
25
Harrow
HROW
$1.74B
$938K 0.57%
180,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Birchview Capital held 53 positions worth $165M, up 47% from $113M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Birchview Capital deployed $21.1M of net new capital in Q2 2020, opening 7 new positions and adding to 8 existing holdings. Its largest new stake was Aspira Women's Health Inc. Common Stock: 219,816 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Discretionary.

On the sell side, the largest reduction was Gilead Sciences, an estimated $766K trimmed.

  • Birchview Capital's largest Q2 2020 buy was Aspira Women's Health Inc. Common Stock: 219,816 shares worth $12.7M.
  • Birchview Capital added most to Soleno Therapeutics in Q2 2020, an estimated $1.81M increase.
  • Birchview Capital's biggest Q2 2020 reduction was Gilead Sciences, cutting an estimated $766K.
  • Birchview Capital fully exited Vermillion, Inc. in Q2 2020, selling an estimated $2.68M.
  • Birchview Capital's ten largest holdings make up 79% of its $165M portfolio in Q2 2020.
  • Birchview Capital opened 7 new positions and closed 2 in Q2 2020.
  • Birchview Capital's portfolio value rose 47% quarter-over-quarter to $165M.

Based on Birchview Capital's 13F filing for Q2 2020, filed 10 Aug 2020.